0001562180-24-001223.txt : 20240209
0001562180-24-001223.hdr.sgml : 20240209
20240209160503
ACCESSION NUMBER: 0001562180-24-001223
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240207
FILED AS OF DATE: 20240209
DATE AS OF CHANGE: 20240209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Metzger Michael A
CENTRAL INDEX KEY: 0001507220
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37708
FILM NUMBER: 24614703
MAIL ADDRESS:
STREET 1: C/O SYNDAX PHARMACEUTICALS, INC.
STREET 2: 400 TOTTEN POND ROAD,
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Syndax Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001395937
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 320162505
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
STREET 2: BUILDING D, FLOOR 3
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-419-1400
MAIL ADDRESS:
STREET 1: 35 GATEHOUSE DRIVE
STREET 2: BUILDING D, FLOOR 3
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-02-07
false
0001395937
Syndax Pharmaceuticals Inc
SNDX
0001507220
Metzger Michael A
C/O SYNDAX PHARMACEUTICALS, INC.
35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3
WALTHAM
MA
02451
true
true
false
false
Chief Executive Officer
false
Common Stock
2024-02-07
4
A
false
107250.00
0.00
A
124909.00
D
Common Stock
2024-02-07
4
A
false
39000.00
0.00
A
163909.00
D
Stock Options (Right to buy)
22.28
2024-02-07
4
A
false
214500.00
22.28
A
2034-02-07
Common Stock
214500.00
214500.00
D
Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested.
Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company.
1/48th of the shares subject to the option shall vest monthly over a four-year period.
/s/ Michael A. Metzger
2024-02-09